Thailand - Delayed Quote THB

MEDEZE_MEDEZE GROUP (MEDEZE-R.BK)

Compare
9.95
-0.25
(-2.45%)
At close: January 27 at 4:35:25 PM GMT+7
Loading Chart for MEDEZE-R.BK
DELL
  • Previous Close 10.20
  • Open 10.10
  • Bid --
  • Ask --
  • Day's Range 9.85 - 10.30
  • 52 Week Range 9.85 - 10.30
  • Volume 20,945,800
  • Avg. Volume --
  • Market Cap (intraday) --
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date Nov 26, 2024
  • 1y Target Est --

Medeze Group Public Company Limited engages in collection and storage of stem cells for use in medication in Thailand, Vietnam, Cambodia, and internationally. The company operates through four segments: Stem Cells; Natural Killer Cells; Others; and Sales of Products. It also provides sorting, cultivation, and development of stem cells; testing services to test the performance and count the number of natural killer cells; and research, develops, and collects data on all types of human cellular activities and medical laboratory test. In addition, the company sells dietary supplements, cosmetics, and dermo cosmetics. The company was founded in 2010 and is based in Nakhon Pathom, Thailand.

www.medezegroup.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: MEDEZE-R.BK

View More

Compare To: MEDEZE-R.BK

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: MEDEZE-R.BK

View More

Valuation Measures

Annual
As of 1/27/2025
  • Market Cap

    10.63B

  • Enterprise Value

    10.41B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    34.66%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    780.07M

  • Net Income Avi to Common (ttm)

    270.4M

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    273.46M

  • Total Debt/Equity (mrq)

    1.74%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: MEDEZE-R.BK

View More

Company Insights: MEDEZE-R.BK

Research Reports: MEDEZE-R.BK

View More